Cohance Lifesciences came under pressure in Thursday’s trade, with the stock sliding more than 6% after the company reported a disappointing set of numbers for the September quarter. As of 9:30 AM, the shares were trading 6.15% lower at Rs 647.50.
The company’s consolidated revenue fell 8% to Rs 556 crore, compared to Rs 604 crore a year earlier, reflecting a subdued operating environment. Operational performance weakened as well, with Ebitda down 41.1% at Rs 121 crore against Rs 205 crore last year. As a result, the Ebitda margin slipped to 21.8%, sharply lower than 34% in the same quarter of the previous year.
Profitability also took a hit. Net profit declined 46.5%, coming in at Rs 74.1 crore versus Rs 139 crore a year ago.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
